Overview

  • Product nameAnti-GFAP antibody [MIG-G2], prediluted
    See all GFAP primary antibodies
  • Description
    Mouse monoclonal [MIG-G2] to GFAP, prediluted
  • SpecificityGFAP, no cross-reactivity with other filament proteins.
  • Tested applicationsSuitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Rat, Guinea pig, Human
  • Immunogen

    Purified Glial Fibrillary Acidic Protein.

  • Positive control
    • Glioma, Astrocytoma.
  • General notes


    ab51838 is helpful in differentiation of central nervous tumours. The antibody will specifically label glioblastoma, astrocytoma and medulloblastoma.

Properties

Applications

Our Abpromise guarantee covers the use of ab51838 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.

60 min at RT. No protease pre-treatment. Blocking of endogenous enzymes is recommended, depending on kind of secondary reagents The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test).

Target

  • FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
  • Tissue specificityExpressed in cells lacking fibronectin.
  • Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
  • Sequence similaritiesBelongs to the intermediate filament family.
  • Post-translational
    modifications
    Phosphorylated by PKN1.
  • Cellular localizationCytoplasm. Associated with intermediate filaments.
  • Information by UniProt
  • Database links
  • Alternative names
    • wu:fb34h11 antibody
    • ALXDRD antibody
    • cb345 antibody
    • etID36982.3 antibody
    • FLJ42474 antibody
    • FLJ45472 antibody
    • GFAP antibody
    • GFAP_HUMAN antibody
    • gfapl antibody
    • Glial fibrillary acidic protein antibody
    • Intermediate filament protein antibody
    • wu:fk42c12 antibody
    • xx:af506734 antibody
    • zgc:110485 antibody
    see all

References for Anti-GFAP antibody [MIG-G2], prediluted (ab51838)

This product has been referenced in:
  • Shields DC  et al. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 95:5768-72 (1998). Read more (PubMed: 9576959) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab51838.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"